Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus

Journal of Infectious Diseases

Volumn 201, Issue 6, 2010, Pages 946-955

  Rockx, Barry ^a,c   Donaldson, Eric ^a   Frieman, Matthew ^a   Sheahan, Timothy ^a   Corti, Davide ^d   Lanzavecchia, Antonio ^d   Baric, Ralph S ^a,b  

^a IL   (Australia)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORONAVIRUS; FEMALE; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CELL LINE; FEMALE; HUMANS; LUNG; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MUTATION; NEUTRALIZATION TESTS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL ENVELOPE PROTEINS;

EID: 77749271177     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/651022     Document Type: Article

References (28)

1. Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology 2003; 8: S9-14.
2. Rockx B, Corti D, Donaldson E, et al. Structural basis for potent crossneutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome Coronavirus challenge. J Virol 2008;82:3220-3235
3. Rockx B, Sheahan T, Donaldson E, et al. Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome Coronavirus isolates that produce fatal disease in aged mice. J Virol 2007; 81:7410-7423
4. Traggiai E, Becker S, Subbarao K, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS Coronavirus. Nat Med 2004; 10:871-875
5. Rockx B, Baas T, Zometzer GA, et al. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory distress syndrome Coronavirus infection infection. J Virol 2009;83:7062-7074
6. Sui J, Li W, Roberts A, et al. Evaluation of human monoclonal antibody 8OR for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol 2005; 79:5900-5906
7. Li F, Li W, Farzan M, Harrison SC. Structure of SARS Coronavirus spike receptor-binding domain complexed with receptor. Science 2005; 309:1864-1868
8. Li W, Zhang C, Sui J, et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 2005;24:1634-1643
9. Sheahan T, Rockx B, Donaldson E, Corti D, Baric R. Pathways of crossspecies transmission of synthetically reconstructed zoonotic severe acute respiratory syndrome Coronavirus. J Virol 2008;82:8721-8732
10. Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993;329:1524-1530
11. Kan B, Wang M, Jing H, et al. Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J Virol 2005; 79:11,92-900.
12. Pak JE, Sharon C, Satkunarajah M, et al. Structural insights into immune recognition of the severe acute respiratory syndrome Coronavirus S protein receptor binding domain. J Mol Biol 2009;388:815-823
13. Bian C, Zhang X, Cai X, et al. Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody. Virology 2009; 383:39-46.
14. He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. Receptor-binding domain of severe acute respiratory syndrome Coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005; 174:4908-4915
15. Hwang WC, Lin Y, Santelli E, et al. Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem 2006; 281:34,610-616
16. Prabakaran P, Gan J, Feng Y, et al. Structure of severe acute respiratory syndrome Coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem 2006; 281:15,829-836
17. Mitsuki YY, Ohnishi K, Takagi H, et al. A single amino acid substitution in the Sl and S2 Spike protein domains determines the neutralization escape phenotype of SARS-sCoV. Microbes Infect 2008; 10:908-915
18. Sui J, Aird DR, Tamin A, et al. Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog 2008;4:e1000197.
19. Bizebard T, Barbey-Martin C, Fleury D, et al. Structural studies on viral escape from antibody neutralization. Curr Top Microbiol Immunol 2001;260:55-64.
20. Sherry B, Mosser AG, Colonno RJ, Rueckert RR. Use of monoclonal antibodies to identify four neutralization immunogens on a common cold Picornavirus, human rhinovirus 14. J Virol 1986; 57:246-257
21. ter Meulen J, van den Brink EN, Poon LL, et al. Human monoclonal antibody combination against SARS Coronavirus: synergy and coverage of escape mutants. PLoS Med 2006; 3:e237.
22. Zhu Z, Chakraborti S, He Y, et al. Potent cross-reactive neutralization of SARS Coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A 2007; 104:12,123-128
23. McRoy WC, Baric RS. Amino acid substitutions in the S2 subunit of mouse hepatitis virus variant V51 encode determinants of host range expansion. J Virol 2008;82:1414-1424
24. Callison SA, Jackwood MW, Hilt DA. Infectious bronchitis virus S2 gene sequence variability may affect S1 subunit specific antibody binding. Virus Genes 1999; 19:143-151
25. Lai SC, Chong PC, Yeh CT, et al. Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome Coronavirus (SARS-CoV). J Biomed Sci 2005; 12:711-727
26. Rudneva IA, Ilyushina NA, Timofeeva TA, Webster RG, Kaverin NV Restoration of virulence of escape mutants of H5 and H9 influenza viruses by their readaptation to mice. J Gen Virol 2005;86:2831-2838
27. Ilyushina N, Rudneva I, Gambaryan A, Bovin N, Kaverin N. Monoclonal antibodies differentially affect the interaction between the hemagglutinin of H9 influenza virus escape mutants and sialic receptors. Virology 2004; 329:33-39
28. Coughlin MM, Babcook J, Prabhakar BS. Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms. Virology 2009;394:39-46.